Onco-Innovations Ltd. is a Canadian biotech company focused on cancer research and treatment, particularly with its product ONC010. While it boasts a strong liquidity position with a current and quick ratio of 12.78 and zero debt, its financial health is concerning due to negative ROE and ROA at -120.1% and -110.7%, respectively. This suggests operational inefficiencies despite its promising sector. The lack of debt is a positive sign, but the negative returns indicate challenges in translating research into profitability.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 12.8x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2024-Q4 (January 31, 2025)